Ikena Oncology Statistics
Total Valuation
Ikena Oncology has a market cap or net worth of $82.52 million. The enterprise value is -$47.12 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, before market open.
Earnings Date | Nov 7, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Ikena Oncology has 48.26 million shares outstanding. The number of shares has increased by 24.03% in one year.
Current Share Class | 41.89M |
Shares Outstanding | 48.26M |
Shares Change (YoY) | +24.03% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 2.52% |
Owned by Institutions (%) | 22.83% |
Float | 13.87M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 124.97 |
Forward PS | n/a |
PB Ratio | 0.61 |
P/TBV Ratio | 0.61 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.32, with a Debt / Equity ratio of 0.06.
Current Ratio | 15.32 |
Quick Ratio | 14.94 |
Debt / Equity | 0.06 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.08% and return on invested capital (ROIC) is -23.54%.
Return on Equity (ROE) | -37.08% |
Return on Assets (ROA) | -22.06% |
Return on Capital (ROIC) | -23.54% |
Revenue Per Employee | $15,326 |
Profits Per Employee | -$1.39M |
Employee Count | 43 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | -63,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.88% in the last 52 weeks. The beta is 0.49, so Ikena Oncology's price volatility has been lower than the market average.
Beta (5Y) | 0.49 |
52-Week Price Change | +6.88% |
50-Day Moving Average | 1.71 |
200-Day Moving Average | 1.58 |
Relative Strength Index (RSI) | 49.84 |
Average Volume (20 Days) | 59,905 |
Short Selling Information
The latest short interest is 129,885, so 0.27% of the outstanding shares have been sold short.
Short Interest | 129,885 |
Short Previous Month | 147,782 |
Short % of Shares Out | 0.27% |
Short % of Float | 0.94% |
Short Ratio (days to cover) | 3.02 |
Income Statement
In the last 12 months, Ikena Oncology had revenue of $659,000 and -$59.60 million in losses. Loss per share was -$1.24.
Revenue | 659,000 |
Gross Profit | -39.91M |
Operating Income | -64.29M |
Pretax Income | -66.78M |
Net Income | -59.60M |
EBITDA | -63.58M |
EBIT | -64.29M |
Loss Per Share | -$1.24 |
Full Income Statement Balance Sheet
The company has $138.03 million in cash and $8.39 million in debt, giving a net cash position of $129.64 million or $2.69 per share.
Cash & Cash Equivalents | 138.03M |
Total Debt | 8.39M |
Net Cash | 129.64M |
Net Cash Per Share | $2.69 |
Equity (Book Value) | 134.23M |
Book Value Per Share | 2.78 |
Working Capital | 132.29M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$61.56 million and capital expenditures -$262,000, giving a free cash flow of -$61.83 million.
Operating Cash Flow | -61.56M |
Capital Expenditures | -262,000 |
Free Cash Flow | -61.83M |
FCF Per Share | -$1.28 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -9,755.24% |
Pretax Margin | -9,053.41% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -3,939.43% |
Dividends & Yields
Ikena Oncology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -24.03% |
Shareholder Yield | -24.03% |
Earnings Yield | -72.22% |
FCF Yield | -74.92% |
Analyst Forecast
The average price target for Ikena Oncology is $3.00, which is 75.44% higher than the current price. The consensus rating is "Buy".
Price Target | $3.00 |
Price Target Difference | 75.44% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | 36.14% |
EPS Growth Forecast (5Y) | -12.74% |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Ikena Oncology has an Altman Z-Score of 0.17 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.17 |
Piotroski F-Score | 1 |